Pharmaceutical composition comprising plasminogen and uses thereof
Pharmaceutical compositions comprising plasminogen or a biologically active variant thereof are disclosed. In an embodiment, the composition comprises a tonicity modifier, a bulking agent, and a stabilising agent and has a pH of about 3.0 to about 10.0. In another embodiment, the composition contains an amount of particles in suspension equal to or greater than 10 μm which is lower than 6000 particles per 100 ml, and preferably lower than 2000 particles per 100 ml. Uses of these compositions as a medicament is contemplated. Various therapeutic uses of these pharmaceutical compositions is also contemplated.
1. A liquid pharmaceutical composition for subcutaneous or intradermal administration to a subject, said composition having an osmolality of 180 mOsm to 350 mOsm and comprising:
native human Glu-plasminogen, or a biologically active variant thereof having at least 90% amino acid sequence identity with native human Glu-plasminogen, in a concentration from 2 mg/ml to 60 mg/ml;
a tonicity modifier, which contains sodium, at a concentration of 30 mM to 100 mM; and
a stabilising agent, which is arginine, an arginine salt, glycine or a glycine salt, in a concentration from 10 to 100 mM;
wherein the composition has a pH of 5.0 to 6.0 and is free of aprotinin.
2. The pharmaceutical composition of claim 1 , wherein the stabilising agent is arginine or an arginine salt.
3. The pharmaceutical composition of claim 1 , wherein the stabilising agent is glycine or a glycine salt.
4. The pharmaceutical composition of claim 1 , wherein the pH is from 5.0 to 5.5.
5. The pharmaceutical composition of claim 1 , wherein the concentration of the native human Glu-plasminogen or biologically active variant thereof is from 5 mg/ml to 30 mg/ml.
6. The pharmaceutical composition of claim 5 , wherein the concentration of the native human Glu-plasminogen or biologically active variant thereof is 30, 20, 10 or 5 mg/ml.
7. The pharmaceutical composition of claim 1 , wherein the stabilising agent is in a concentration of 25 mM to 75 mM.
8. The pharmaceutical composition of claim 1 , wherein the tonicity modifier is sodium chloride.
9. The pharmaceutical composition of claim 1 , wherein the tonicity modifier is present in a concentration of 35 mN to 75 nM.
10. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises native human Glu-plasminogen.
11. The pharmaceutical composition of claim 1 , wherein the composition contains an amount of particles equal to or greater than 10 μm that is lower than 2000 particles per (i) 100 ml or per (ii) container with a nominal content of less than or equal to 100 mL.
12. The pharmaceutical composition of claim 11 , wherein the composition contains an amount of particles equal to or greater than 10 μm that is lower than 1000 particles per (i) 100 ml or per (ii) container with a nominal content of less than or equal to 100 mL.
13. The pharmaceutical composition of claim 1 , which is suitable for subcutaneous administration.
14. The pharmaceutical composition of claim 1 , which is a reconstituted composition.
15. A method for treating a plasminogen-deficiency in a subject, wherein said method comprises administering to a subject the pharmaceutical composition of claim 1 .
16. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is free of protease inhibitor.
17. The pharmaceutical composition of claim 1 , further comprising an acetate buffer.
18. The pharmaceutical composition of claim 1 , which comprises an acetate buffer having a pH of 5.0 to 5.5 and:
5 mg/ml to 20 mg/ml native human Glu-plasminogen;
35 mM to 75 mM of sodium chloride; and
25 mM to 75 mM of arginine or an arginine salt.